Hansa Biopharma's Phase 3 Trial for Anti-GBM Disease Fails Primary Endpoint Despite Improved Dialysis-Free Outcomes
核心洞察
Hansa Biopharma (搜索)'s GOOD-IDES-02 Phase 3 trial testing imlifidase for anti-glomerular basement membrane disease (搜索) failed to meet its primary endpoint of improved renal function at 6 months.
Despite the primary endpoint failure, approximately 60% of patients treated with imlifidase plus standard of care avoided dialysis at 6 months, nearly three-fold higher than historical outcomes of 20-25%.
The control arm receiving standard of care alone showed similar treatment response, indicating that the improved outcomes may be attributed to the aggressive treatment protocol rather than imlifidase specifically.
Hansa Biopharma (搜索) announced that its pivotal Phase 3 trial GOOD-IDES-02 evaluating imlifidase for anti-glomerular basement membrane (搜索) (anti-GBM) disease failed to meet its primary endpoint of improved renal function at 6 months, as measured by estimated glomerular filtration rate (eGFR). The disappointing results represent a setback for patients with this rare, severe autoimmune condition that affects approximately 1.6 people per million annually.
Trial Results Show Mixed Outcomes
Despite missing the primary endpoint, the trial revealed encouraging secondary outcomes. Approximately 60% of patients treated with imlifidase followed by standard of care (SoC) did not require dialysis at 6 months, representing a substantial improvement compared to historical control cohorts where only 20-25% of patients typically avoid dialysis at this timepoint. However, patients in the control arm receiving SoC alone showed similar treatment responses, suggesting the improved outcomes may be attributed to the aggressive treatment protocol rather than imlifidase specifically.
The standard of care protocol was defined as immediate and intense plasma exchange (PLEX) combined with cyclophosphamide and glucocorticoids (搜索). The administration of imlifidase in combination with SoC proved well tolerated with an acceptable safety profile, consistent with observations from other imlifidase clinical trials.
Company and Investigator Perspectives
"We are disappointed not to be able to provide a new treatment option for this patient group, who to date have experienced poor outcomes," said Renée Aguiar-Lucander, CEO of Hansa Biopharma (搜索). "Despite the deep and rapid reduction of anti-GBM antibodies (搜索) following imlifidase treatment, it did not result in a statistically significant outcome in this setting."
Aguiar-Lucander noted the company remains optimistic about imlifidase's potential in other applications, stating they are "on track to file our BLA with the FDA, related to desensitization of highly sensitized patients on the waitlist for kidney transplant, before the year end."
Professor Mårten Segelmark, International Coordinating Investigator in GOOD-IDES-02, offered a measured perspective: "Although the trial did not meet the primary endpoint, the overall outcome, in terms of avoiding dialysis dependency, is encouraging as it shows that anti-GBM patients clearly benefit from receiving a more aggressive treatment compared to what has previously been achieved in clinical practice."
Trial Design and Patient Population
GOOD-IDES-02 was an open-label, multi-center Phase 3 trial conducted across over 50 sites in 14 countries throughout the EU, US, and UK. The study enrolled 50 adult patients, with 25 randomized to receive imlifidase in combination with SoC and 25 receiving SoC treatment alone.
The primary objective assessed the effect on kidney function of imlifidase combined with SoC versus SoC alone in patients with severe anti-GBM disease. Primary and key secondary endpoints were evaluated at 6 months through renal function measurements and dialysis requirements. Additional outcomes included effects on anti-GBM antibody and ANCA levels, other kidney function measures, health-related quality of life, and safety parameters.
Disease Background and Unmet Need
Anti-glomerular basement membrane disease (搜索), also known as Goodpasture disease (搜索), represents a rare but devastating autoimmune condition where the immune system develops antibodies against glomerular basement membrane (搜索) antigens. This results in acute immune attacks on the kidneys and, in approximately half of patients, the lungs. Approximately two-thirds of anti-GBM patients experience kidney failure (搜索) requiring long-term dialysis while awaiting potential kidney transplantation, and the condition proves fatal in one out of six patients during the acute phase.
Imlifidase, a unique antibody-cleaving enzyme derived from Streptococcus pyogenes, specifically targets IgG (搜索) antibodies and has received orphan drug designation for anti-GBM disease treatment from both the U.S. FDA and European Medicines Agency. The drug has conditional marketing approval in the EU, UK, Switzerland, and Australia under the trade name IDEFIRIX for desensitizing highly sensitized adult kidney transplant patients.
Future Implications
While the trial results represent a setback for anti-GBM disease treatment development, the improved dialysis-free outcomes observed across both treatment arms suggest that more aggressive standard of care protocols may benefit this patient population. Patients in the trial continue to be followed for 24 months after randomization, with long-term outcomes to be reported separately, potentially providing additional insights into treatment durability and patient outcomes.